Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
Rex Wan-Hin HuiLung Yi MakWai-Kay SetoMan-Fung YuenPublished in: Expert opinion on emerging drugs (2022)
Among novel HBV antivirals, RNA silencers, viral protein export inhibitors (with pegylated interferon), and entry inhibitors (with pegylated interferon) appear to be effective in suppressing HBsAg and may even induce functional cure. The other virus-targeting agents have variable effects on HBV DNA, HBsAg, HBeAg, and HBcrAg. Immunomodulators have modest effects on HBsAg but may have important roles in combination therapy. Upcoming trials will answer important questions on ideal dosing, long-term drug effects, and efficacy of combination regimens.
Keyphrases
- hepatitis b virus
- combination therapy
- phase ii
- clinical trial
- open label
- liver failure
- dendritic cells
- phase iii
- double blind
- placebo controlled
- signaling pathway
- circulating tumor
- single molecule
- cancer therapy
- nucleic acid
- recombinant human
- immune response
- protein protein
- small molecule
- randomized controlled trial
- amino acid
- replacement therapy